REDWOOD
CITY, Calif., Feb. 29,
2024 /PRNewswire/ -- Arcellx, Inc. (NASDAQ: ACLX), a
biotechnology company reimagining cell therapy through the
development of innovative immunotherapies for patients with cancer
and other incurable diseases, today announced that management will
participate in a fireside chat at the TD Cowen 44th Annual Health
Care Conference on Wednesday, March
6, at 2:50 p.m. ET.
A live webcast of this discussion will be accessible from
Arcellx's website at www.arcellx.com in the Investors section.
A replay of the webcast will be archived and available for 30 days
following the event.
About Arcellx, Inc.
Arcellx, Inc. is a clinical-stage biotechnology company reimagining
cell therapy by engineering innovative immunotherapies for patients
with cancer and other incurable diseases. Arcellx believes that
cell therapies are one of the forward pillars of medicine and
Arcellx's mission is to advance humanity by developing cell
therapies that are safer, more effective, and more broadly
accessible. Arcellx's lead product candidate, anito-cel (formerly
CART-ddBCMA), is being developed for the treatment of relapsed or
refractory multiple myeloma (rrMM) in a Phase 2 pivotal trial.
Anito-cel has been granted Fast Track, Orphan Drug, and
Regenerative Medicine Advanced Therapy designations by the U.S.
Food and Drug Administration.
Arcellx is also developing its dosable and controllable CAR T
therapy, ARC-SparX, through two Phase 1 programs, ACLX-001 for rrMM
and ACLX-002 in relapsed or refractory acute myeloid leukemia and
high-risk myelodysplastic syndrome. For more information on
Arcellx, please visit www.arcellx.com. Follow Arcellx on
X (Twitter) at @arcellx and LinkedIn.
Forward-looking Statements
This press release contains forward-looking statements within the
meaning of Section 27A of the Securities Act of 1933, as amended,
and Section 21E of the Securities Exchange Act of 1934, as amended.
All statements in this press release that are not purely historical
are forward-looking statements, including Arcellx's expectations
regarding the timing and outcomes of clinical trials for its
product candidates and the potential impact of its product
candidates and platforms on patients and cell therapy. The
forward-looking statements contained herein are based upon
Arcellx's current expectations and involve assumptions that may
never materialize or may prove to be incorrect. These
forward-looking statements are neither promises nor guarantees and
are subject to a variety of risks and uncertainties, including
risks that may be found in the section entitled "Part I, Item 1A
(Risk Factors) in the Annual Report on Form 10-K for the fiscal
year ended December 31, 2023, filed
with the Securities and Exchange Commission (SEC) on February 28, 2024, and other documents that
Arcellx files from time to time with the SEC. These forward-looking
statements are made as of the date of this press release, and
Arcellx assumes no obligation to update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as required by law.
Investors:
Myesha Lacy
ir@arcellx.com
510-418-2412
Media:
Andrea Cohen Sam Brown Inc.
andreacohen@sambrown.com
917-209-7163
View original content to download
multimedia:https://www.prnewswire.com/news-releases/arcellx-to-participate-at-the-td-cowen-44th-annual-health-care-conference-302076323.html
SOURCE Arcellx, Inc.